Related Experiment Video
Updated: Aug 16, 2026
Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
Published on: June 29, 2014
Aldosterone and heart failure
1Department of Cardiology, University Henri Poincaré, Hôpital Central, Nancy, France.
Insights
In congestive heart failure, elevated aldosterone levels worsen disease severity and contribute to cardiac damage. Further research is needed to explore aldosterone antagonists for improved patient outcomes.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Elevated aldosterone plasma concentrations are characteristic of untreated congestive heart failure, escalating with disease severity.
- Diuretic use further increases aldosterone levels, while Angiotensin II, potassium, and corticotropin are key stimulators.
- Aldosterone contributes to adverse cardiac remodeling, electrical instability, and vasoconstriction, impacting heart failure progression.
Purpose of the Study:
- To review the role of aldosterone in congestive heart failure.
- To discuss the impact of aldosterone on cardiac pathophysiology and mortality.
- To highlight the potential therapeutic benefits of aldosterone antagonists.
Main Methods:
- Literature review of experimental and clinical studies on aldosterone in heart failure.
- Analysis of aldosterone regulation and its physiological effects.
- Evaluation of current and potential pharmacological interventions.
Main Results:
- Aldosterone levels correlate with heart failure severity and are influenced by treatments like diuretics and ACE inhibitors.
- Aldosterone promotes sodium/water retention, hypokalemia, hypomagnesemia, cardiac hypertrophy, fibrosis, and vasoconstriction.
- High aldosterone levels are linked to reduced baroreflex sensitivity and increased mortality in severe heart failure.
Conclusions:
- Aldosterone plays a significant detrimental role in congestive heart failure pathophysiology.
- Targeting aldosterone with specific antagonists may offer therapeutic benefits.
- Further research is warranted to develop potent aldosterone-blocking agents with favorable side-effect profiles.
Abstract:
In untreated congestive heart failure, aldosterone plasma concentrations are elevated in proportion to the severity of the disease and are further increased by the use of diuretic treatment. Angiotensin II, plasma potassium concentration, and corticotropin are the major stimulators of aldosterone synthesis. During angiotensin converting enzyme (ACE) inhibition, the role of alternative major or minor regulatory mechanisms may become significant. This may explain why during continuous ACE inhibition, after an initial reduction, plasma aldosterone measurements may subsequently increase to pretherapeutic levels. In addition to causing sodium and water retention, aldosterone contributes to hypokalaemia and hypomagnesaemia, which may induce electrical instability and death of cardiac myocytes. Aldosterone is also one factor involved in cardiac hypertrophy and fibrosis, which, together with myocardial cell death, may underlie progressive adverse myocardial remodelling. Evidence for a direct vascular effect of aldosterone suggests that this hormone may contribute to generalized vasoconstriction. Elevated plasma aldosterone levels can also contribute to depression of baroreflex sensitivity, and they are associated with increased mortality in patients with severe heart failure. Experimental and clinical research should be further expanded to investigate the potential benefits of opposing the effects of aldosterone by use of specific antagonists or other potentially more potent pharmacological agents with favourable side-effect profiles.
Related Concept Videos
01:33Hormonal Regulation
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
01:22Heart Failure Drugs: Diuretics
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: β-Blockers
01:29Heart Failure II: Pathophysiology